Myeloproliferative Neoplasms | Specialty

FDA Grants Fast Track Designation to Nuvisertib for Myelofibrosis

June 13th 2025

The FDA granted fast track designation to nuvisertib for intermediate- or high-risk myelofibrosis.

New EBMT Machine Learning Model Outperforms Available Tools in Predicting Transplant Risk in Myelofibrosis

June 12th 2025

The EBMT have developed a machine learning model designed to identify and stratify transplant risk for patients with myelofibrosis.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Rusfertide Shines as New Treatment Option in Polycythemia Vera

June 2nd 2025

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Luspatercept Increases Likelihood of Lasting Transfusion Independence in ESA-Naive, Lower-Risk MDS

May 31st 2025

Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

May 29th 2025

Pelabresib/Ruxolitinib Improves Spleen Responses in JAK Inhibitor–Naive Myelofibrosis

May 29th 2025

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

Dr Atluri on TKI Selection in Chronic Myeloid Leukemia

May 28th 2025

Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.

Asciminib Shows Early Activity With Multiple TKIs in Chronic Myeloid Leukemia

May 27th 2025

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

SVR With Pacritinib Is Linked With OS Benefit in Myelofibrosis With Thrombocytopenia

May 26th 2025

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis

May 24th 2025

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Dr Sekeres on the Methods and Design of a Study Evaluating Smoking Implications in MDS

May 22nd 2025

Mikkael A. Sekeres, MD, discusses the design of a study assessing the correlation between smoking intensity and genetic mutations in patients with MDS.

Olutasidenib Displays High Response Rates in IDH1-Mutated AML Arising From a Prior Myeloproliferative Neoplasm

May 22nd 2025

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Hunter on the Role of Momelotinib as First-Line Therapy in Myelofibrosis

May 19th 2025

Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dr Gerds on the Development of Anemia in Low-Risk Myelofibrosis

May 7th 2025

Aaron Gerds, MD, details the prevalence of anemia in patients with low- to intermediate-1–risk myelofibrosis.

FDA Grants Fast Track Designation to Givinostat for Polycythemia Vera

May 6th 2025

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

Dr Hernández-Boluda on Machine Learning for Identifying Transplant Risk in Myelofibrosis

May 5th 2025

Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis

April 30th 2025

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.